Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma.

Abstract:

:Loss of function of the ataxia-telangiectasia mutated (ATM) gene, located on human chromosome 11q22-23, is the cause of ataxia-telangiectasia (A-T), which is associated with an extremely high risk for lymphoma. Abnormalities in 11q22-23, including deletions and mutations of the ATM gene, have been reported in T-cell prolymphocytic leukemias, B-CLL and in mantle cell lymphoma. In a survey of gene expression in follicle center lymphomas (FCL) and diffuse large B-cell lymphomas (DLBCL), almost all FCL expressed significant levels of ATM and the majority of DLBCL expressed low levels of ATM. This finding raised the possibility that the transformation of some FCL to DLBCL might be associated with inactivation of the ATM gene. Therefore, we analyzed biopsy specimens of 17 patients with FCL obtained at the time of diagnosis, four subsequent biopsies obtained at the time of FCL relapse and seven subsequent biopsies at the time of transformation to DLBCL. A comprehensive analysis of the ATM gene was performed by denaturing high performance liquid chromatography and sequencing. The analysis covered all of the 66 exons including the 9168 base pairs of ATM coding sequence as well as 16,676 base pairs of non-coding sequence. Twenty-eight known polymorphisms and rare sequence variants were observed, but no classic A-T mutations were detected. In 11 tumors, both tumor B-cells and normal T-cells were sorted for separate examination, and in each case, polymorphisms and rare variants were present in both tumor and normal cells. No new ATM gene mutations were associated with transformation from FCL to DLBCL. Thus, ATM gene mutations do not play a pivotal role either in the pathogenesis of FCL or in its transformation to DLBCL.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Lossos IS,Thorstenson YR,Wayne TL,Oefner PJ,Levy R,Chu G

doi

10.1080/10428190290021623

keywords:

subject

Has Abstract

pub_date

2002-05-01 00:00:00

pages

1079-85

issue

5

eissn

1042-8194

issn

1029-2403

journal_volume

43

pub_type

杂志文章
  • Coexistent multiple myeloma and myelofibrosis.

    abstract::Although the association of bone marrow fibrosis with plasma cell dyscrasias has already been described in several reports, the close relationship between these entities still remains unclear. In this report we describe a patient with clinical and pathologic findings which initially suggested a diagnosis of myelofibro...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309148567

    authors: Pulsoni A,Bianco P,La Verde G,Mecarocci S,Petrucci MT,Torromeo C,Avvisati G

    更新日期:1993-07-01 00:00:00

  • Nuclear Topoisomerase II Activity Changes During HL-60 Leukemic Cell Differentiation: Alterations in Drug Sensitivity and pH Dependency.

    abstract::We have studied the effect of dimethyl-sulfoxide(DMSO)-induced granulocytic differentiation on the sensitivity of HL-60 cells to various cytotoxic topoisomerase II inhibitors: (i) undifferentiated HL-60 cells are highly sensitive to etoposide, while differentiated HL-60 cells are 700-1000 fold resistant to etoposide, ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068137

    authors: Gieseler F,Boege F,Biersack H,Spohn B,Clark M,Wilms K

    更新日期:1991-01-01 00:00:00

  • Radon and Acute Lymphoblastic Leukaemia.

    abstract::The incidence of Acute Lymphoblastic Leukaemia (A.L.L.) in an L.R.P. data collection survey has been compared with the indoor radon and gamma-ray exposure in 22 administrative counties in England and Wales. There is a strong correlation (r = 0.56, p < 0.01) for the incidence of childhood A.L.L. and indoor radon concen...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009050998

    authors: Lucie NP

    更新日期:1990-01-01 00:00:00

  • Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.

    abstract::Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from or are refractory to systemic chemotherapy remains unclear. Romidepsin is a potent, class-I selective histone deacetyla...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1361022

    authors: Duvic M,Bates SE,Piekarz R,Eisch R,Kim YH,Lerner A,Robak T,Samtsov A,Becker JC,McCulloch W,Waksman J,Whittaker S

    更新日期:2018-04-01 00:00:00

  • Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas.

    abstract::Akt (protein kinase B) is a serine/threonine kinase involved in the regulation of cell survival signals. Akt is expressed in T- and B-lymphocytes and is activated in response to cytokine and antigen-receptor stimulation. Three isoforms of Akt have been identified, Akt-1, -2 and -3, but the expression pattern and speci...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500159944

    authors: Fillmore GC,Wang Q,Carey MJ,Kim CH,Elenitoba-Johnson KS,Lim MS

    更新日期:2005-12-01 00:00:00

  • Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients.

    abstract::In acute myeloid leukemia (AML), cytogenetics predicts treatment outcome for the favorable and poor subgroups but not for the intermediate subgroup. Polymorphisms within the nucleotide excision repair (NER) pathway may lead to interindividual differences in DNA repair capacity, influencing outcome. We studied the role...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903582804

    authors: Strom SS,Estey E,Outschoorn UM,Garcia-Manero G

    更新日期:2010-04-01 00:00:00

  • Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features.

    abstract::Simultaneous occurrence of hairy cell leukemia (HCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (termed CLL) is very rare. Clinical characteristics, pathology and management of these cases have not been well described. We present six patients with CLL and HCL or HCL variant (HCL-v). Of six patients, t...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1797007

    authors: Obiorah IE,Francischetti IMB,Wang HW,Ahn IE,Wang W,Raffeld M,Kreitman RJ,Wiestner A,Calvo KR

    更新日期:2020-12-01 00:00:00

  • A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.

    abstract::Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3109/10428194.2010.543714

    authors: Furman RR,Grossbard ML,Johnson JL,Pecora AL,Cassileth PA,Jung SH,Peterson BA,Nadler LM,Freedman A,Bayer RL,Bartlett NL,Hurd DD,Cheson BD,Cancer Leukemia Group B.,Eastern Cooperative Oncology Group.

    更新日期:2011-04-01 00:00:00

  • Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.

    abstract::In the rituximab era, several large studies have suggested that full-dose rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) might be the best treatment for patients with diffuse large B-cell lymphoma (DLBCL) aged 60 years and older. However, it remains unclear whether this is also the c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.600486

    authors: Meguro A,Ozaki K,Sato K,Oh I,Fujiwara S,Hosonuma R,Sasazaki M,Kikuchi Y,Hirata Y,Yamamoto C,Uesawa M,Kobayashi H,Matsu H,Okabe H,Uehara E,Nishikawa A,Tatara R,Hatano K,Yamamoto C,Matsuyama T,Toshima M,Ueda M,O

    更新日期:2012-01-01 00:00:00

  • Acute myelogenous leukemia associated with a mediastinal tumor.

    abstract::We describe a 45-year-old female who developed acute myelogenous leukemia (AML) associated with a mediastinal mass. The patient achieved a complete remission accompanied by resolution of the mediastinal mass following intensive chemotherapy alone. A review of the literature disclosed ten AML patients with a mediastina...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309059583

    authors: Chubachi A,Miura I,Takahashi N,Nimura T,Imai H,Miura AB

    更新日期:1993-12-01 00:00:00

  • Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.

    abstract::Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent d...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600565057

    authors: Faber E,Nausová J,Jarosová M,Egorin MJ,Holzerová M,Rozmanová S,Maresová I,Divoký V,Indrák K

    更新日期:2006-06-01 00:00:00

  • Central venous catheter-related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures.

    abstract:UNLABELLED:We retrospectively analyzed the incidence of thrombotic and infectious complications in relation with the use of central venous catheters (CVCs), in a series of patients with hematological malignancies and low platelet and leucocyte counts. PATIENTS AND METHODS:126 patients with hematological malignancies w...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190309178770

    authors: Cortelezzia A,Fracchiolla NS,Maisonneuve P,Moia M,Luchesini C,Ranzi ML,Monni P,Pasquini MC,Lambertenghi-Deliliers G

    更新日期:2003-09-01 00:00:00

  • Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.

    abstract::131 patients with Philadelphia (Ph') chromosome positive chronic myelogenous leukemia (CML) were treated with interferon (IFN) alpha or a combination of IFN alpha and IFN gamma. In study, 1, 13 not pretreated and 41 pretreated patients, 48 in chronic phase disease, 6 in accelerated phase, received 4 x 10(6) U/m2 IFN a...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3109/10428199309148513

    authors: Niederle N,Kloke O,Wandl UB,Becher R,Moritz T,Opalka B

    更新日期:1993-01-01 00:00:00

  • Acute myelogenous leukemia complicated by acute necrotizing ulcerative gingivitis due to Aspergillus terreus.

    abstract::Infections caused by Aspergillus terreus are rare but have been associated with a poor outcome in immunocompromised patients due to frequent resistance to conventional antifungal therapy. This report describes a case of a woman who developed acute necrotizing ulcerative gingivitis (ANUG) due to A. terreus during induc...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000060573

    authors: Khoury H,Poh CF,Williams M,Lavoie JC,Nevill TJ

    更新日期:2003-04-01 00:00:00

  • Treatment of advanced Hodgkin's disease: EBVD versus intensive brief chemotherapy.

    abstract::We start a controlled clinical trial to assess efficacy and toxicity of EBVD (epirubicin, bleomycin, vinblastine and dacarbazine) with an intensive and brief program of seven drugs administered weekly for 12 weeks in previously untreated patients with advanced Hodgkin's disease. Two hundred and sixty four patients wer...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1080/1042819031000067729

    authors: Avilés A,Cleto S,Neri N,Huerta-Guzmán J,Talavera A,Castañeda C,González M

    更新日期:2003-08-01 00:00:00

  • Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.

    abstract::There are limited effective therapies for most patients with relapsed diffuse large B-cell lymphoma (DLBCL). We conducted a phase II trial of the multi-targeted vascular endothelial growth factor receptor (VEGFR) kinase inhibitor, sunitinib, 37.5 mg given orally once daily in adult patients with relapsed or refractory...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.555892

    authors: Buckstein R,Kuruvilla J,Chua N,Lee C,Macdonald DA,Al-Tourah AJ,Foo AH,Walsh W,Ivy SP,Crump M,Eisenhauer EA

    更新日期:2011-05-01 00:00:00

  • Cytogenetics of hybrid acute leukemias.

    abstract::Although the recognition of hybrid acute leukemia (HAL) is still controversial, several reports have described cytogenetic findings in these leukemias over the last 3 years. A distinct chromosomal profile appears to be associated with different immunologic subsets of HAL. The classical t(15;17), and inv(16) as well as...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509075298

    authors: Cuneo A,Boogaerts M,Ferrant A,Michaux JL,Bosly A,Louwagie A,Van den Berghe H,Balsamo R,Roberti G,Bardi A

    更新日期:1995-01-01 00:00:00

  • A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells.

    abstract::Clonal bone marrow (BM) B-cell populations are a common finding in patients with suspected primary central nervous system lymphoma (PCNSL). To assess their clinical significance, benign monoclonal B-cell lymphocytosis (MBL) needs to be differentiated from concomitant BM involvement, since patients with secondary centr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1482538

    authors: Brandt A,Matschke J,Fehrle W,von Wenserski L,Bokemeyer C,Illerhaus G,Binder M

    更新日期:2019-02-01 00:00:00

  • Acute promyelocytic leukemia, hypogranular variant, with uncharacteristic staining with chloroacetate esterase.

    abstract::A diagnosis of the hypogranular variant of acute promyelocytic leukemia (APLv) may be difficult to establish based on cytomorphology alone. However, the great majority of cases have a classical immunophenotype by flow cytometric immunophenotyping (FCI) (CD13+, CD33+, dim CD64+, HLA-DR-, and CD34-) and a classical enzy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097693

    authors: Dunphy CH,Polski JM,Johns G,Evans HL,Gardner LJ

    更新日期:2001-06-01 00:00:00

  • Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.

    abstract::We investigated the role of the leptin receptor (Ob-R) and its relationship with PI3K/AKT activation in diffuse large B-cell lymphoma (DLBCL) clinical samples followed by in vitro studies using a panel of CRC cell lines. Leptin exerts its physiological action through its receptor Ob-R. Overexpression of Ob-R has been ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428191003802365

    authors: Uddin S,Bu R,Ahmed M,Hussain AR,Ajarim D,Al-Dayel F,Bavi P,Al-kuraya KS

    更新日期:2010-07-01 00:00:00

  • Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation.

    abstract::Human herpes virus type 6 can reactivate in patients after allogeneic stem cell transplantation and has been associated with serious sequelae such as delayed engraftment and an increased risk of developing acute graft-versus-host disease (GVHD). This study investigated human herpes virus type 6 (HHV-6) reactivation wi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2016.1157873

    authors: Cirrone F,Ippoliti C,Wang H,Zhou XK,Gergis U,Mayer S,Shore T,van Besien K

    更新日期:2016-11-01 00:00:00

  • Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission.

    abstract::The capacity to generate effective dendritic cells (DC) from adult acute lymphoblastic leukemia (ALL) patients in complete remission (CR) and off-therapy was investigated. Monocyte-derived DC cultured in the presence of granulocyte-macrophage colony-stimulating factor, interleukin (IL)-4 and tumor necrosis factor (TNF...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190601101001

    authors: Maggio R,Peragine N,Calabrese E,De Propris MS,Intoppa S,Della Starza I,Ariola C,Vitale A,Foà R,Guarini A

    更新日期:2007-02-01 00:00:00

  • Lymphocyte function-associated antigen-1 and intercellular adhesion molecule-1 expression on B-cell subsets and the effects of splenectomy-experimental studies.

    abstract::There is an abundance of data dealing with recirculation of T cells in the rats, but relatively little is known about the traffic of B cells. The adhesion molecules expressed on the surface membrane are of great significance for recirculation of lymphocytes. However, very little is known about the expression of variou...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819021000033006

    authors: Milićević NM,Milićević Z,Westermann J

    更新日期:2002-11-01 00:00:00

  • Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.

    abstract::The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with de-novo DLBCL and 16 with transformed lymp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1824069

    authors: Segman Y,Ribakovsky E,Avigdor A,Goldhecht Y,Vainstein V,Goldschmidt N,Harlev S,Horwitz N,Gutwein O,Gurion R,Itchaki G,Abadi U,Nemets A,Sofer O,Zektser M,Tadmor T,Dally N,Filanovsky K,Leiba M,Sarid N,Benyamini N,

    更新日期:2021-01-01 00:00:00

  • Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.

    abstract::The aim of the study was efficacy and toxicity evaluation of combination of 2-Chlorodeoxyadenosine (2-CdA) with cytarabine (Ara-C) and G-CSF (CLAG regimen) as reinduction therapy in patients with refractory or relapsed acute myeloid leukemia (AML). The protocol stipulated an infusion of 5 mg/m2 of 2-CdA over 2 hours d...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009053545

    authors: Robak T,Wrzesień-Kuś A,Lech-Marańda E,Kowal M,Dmoszyńska A

    更新日期:2000-09-01 00:00:00

  • NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFκB and JNK.

    abstract::The t(5;17) variant of acute promeylocytic leukemia (APL) expresses a fusion of nucleophosmin (NPM) with the retinoic acid receptor alpha (RARA). We have previously shown that NPM-RAR is a binding partner of the tumor necrosis factor (TNF) receptor type-I-associated DEATH domain protein, TRADD. Binding of TNF to its r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1023799

    authors: Chattopadhyay A,Abecassis I,Redner RL

    更新日期:2015-01-01 00:00:00

  • Long non-coding RNA GAS5 polymorphism predicts a poor prognosis of acute myeloid leukemia in Chinese patients via affecting hematopoietic reconstitution.

    abstract::Whether long non-coding RNA (lncRNA) single-nucleotide polymorphisms (SNPs) affect prognosis of acute myeloid leukemia (AML) remains unknown. To search the association between lncRNA SNPs and AML outcomes, thirty tagSNPs in five lncRNAs were genotyped in 313 AML patients. Survival analysis indicated that GAS5 rs558296...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1266626

    authors: Yan H,Zhang DY,Li X,Yuan XQ,Yang YL,Zhu KW,Zeng H,Li XL,Cao S,Zhou HH,Zhang W,Chen XP

    更新日期:2017-08-01 00:00:00

  • A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.

    abstract::The purpose of this phase 2 study was to determine the activity and safety of six cycles of bendamustine and eight rituximab (RB) as first-line treatment of adult patients with advanced stage non-follicular indolent non-Hodgkin lymphomas (INFL). The primary end-point was the complete response rate (CRR) with expected ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2015.1091934

    authors: Luminari S,Goldaniga M,Cesaretti M,Orsucci L,Tucci A,Pulsoni A,Salvi F,Arcaini L,Carella AM,Tedeschi A,Pinto A,Stelitano C,Baldini L

    更新日期:2016-01-01 00:00:00

  • Correlation of bcl-2 with P-glycoprotein expression in chronic lymphocytic leukaemia and other haematological neoplasms but of neither marker with ex vivo chemosensitivity or patient survival.

    abstract::We compared bcl-2 with P-glycoprotein expression (C494 and JSB1), and both with ex vivo chemosensitivity by Differential Staining Cytotoxicity (DiSC) assay (25 cytotoxic drugs), in 76 fresh haematological specimens, including 51 chronic lymphocytic leukaemias (CLL). Strong correlations were seen between bcl-2 and Pgp ...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199609045722

    authors: Bosanquet AG,Bell PB,Burlton AR,Amos TA

    更新日期:1996-12-01 00:00:00

  • Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells.

    abstract::Patients with hematological malignancies who relapse after bone marrow transplantation (BMT) are often treated with donor lymphocyte infusion. However, this procedure often results in graft-versus-host disease (GVHD). While, Dendritic cells (DCs), which present antigens to naive T cells, have been used in the immunoth...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428190109064592

    authors: Fujii S,Shimizu K,Fujimoto K,Kiyokawa T,Tsukamoto A,Sanada I,Kawano F

    更新日期:2001-07-01 00:00:00